Organ-on-chip applications in drug discovery: an end user perspective.
| Autor: | Clapp N; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K., Amour A; Refractory Respiratory Inflammation Discovery Performance Unit, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K., Rowan WC; Novel Human Genetics Research Unit GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K., Candarlioglu PL; In vitro/In vivo Translation-Complex In Vitro Models, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Biochemical Society transactions [Biochem Soc Trans] 2021 Aug 27; Vol. 49 (4), pp. 1881-1890. |
| DOI: | 10.1042/BST20210840 |
| Abstrakt: | Organ-on-chip (OoC) systems are in vitro microfluidic models that mimic the microstructures, functions and physiochemical environments of whole living organs more accurately than two-dimensional models. While still in their infancy, OoCs are expected to bring ground-breaking benefits to a myriad of applications, enabling more human-relevant candidate drug efficacy and toxicity studies, and providing greater insights into mechanisms of human disease. Here, we explore a selection of applications of OoC systems. The future directions and scope of implementing OoCs across the drug discovery process are also discussed. (© 2021 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|